Quigley neurology, inflammation news

Quigley will reduce spending in its Quigley Pharma Inc. subsidiary to focus on its OTC programs. The company said it may make "further reasonable investment" in QR333, a topical formulation of quercetin, ascorbyl palmitate and vitamin D3 which missed the primary endpoints in a Phase IIb trial for diabetic peripheral neuropathy (DPN); QR440, a botanical broad-spectrum anti-inflammatory compound in preclinical testing to treat inflammation and joint pain; and veterinary compound QR448. Also, Quigley Pharma EVP and COO Richard Rosenblum departed the company, but remains as a consultant. ...